Is there research on the BPC-157 and TB-500 combination specifically?

Not in the published work this page draws on. Every source in the reference list studies one compound or the other. No controlled study tested the pair against either compound alone, so there is no combination effect size to report and no basis for saying the two work better together than separately. That gap is worth stating plainly, because the pairing is usually presented as though it had been demonstrated.

What does stacking actually mean in practice?

Two separate vials, handled separately. BPC-157 and TB-500 arrive as separate lyophilized powders, are reconstituted separately with bacteriostatic water, and are stored and tracked separately once reconstituted. They are not combined in one vial. The vial strengths also differ in our catalog, 20mg per vial for BPC-157 against 10mg per vial for TB-500, so the concentration math is worked out per vial rather than once for both. The reconstitution calculator does that arithmetic in units.

Can BPC-157 and TB-500 be mixed in the same vial?

They are supplied as two separate vials and reconstituted separately. Combining research compounds in one container changes what is in that container and makes it impossible to tell later which material a given result or a given problem came from. The single-vial route that does exist is a blend manufactured as one product, KLOW, rather than two vials mixed at home.

What is the KLOW blend and how does it relate to this pairing?

KLOW is a four-peptide research blend in a single 80mg vial: BPC-157, TB-500, GHK-Cu and KPV. It contains the two compounds on this page plus two more, so it is broader than the pair rather than a packaged version of it. The trade is fixed against flexible. A blend supplies a ratio set at manufacture in one vial and one reconstitution, while separate vials leave each compound independent of the others. Neither arrangement has combination outcome evidence behind it.

What dose does the research report for the stack?

This page does not provide dosing. There is no established human dose for either compound, because the human trial base that would define one does not exist, and quantities used in animal studies are not a template for personal use. A page like this can describe what published research reports. It cannot and should not set a protocol, and any decision about a research compound belongs with a qualified clinician.

Research explainer

The BPC-157 and TB-500 Stack

Q: Why are BPC-157 and TB-500 stacked together?

Because the published primary mechanisms are distinct, even though they converge downstream. BPC-157 is studied for cytoprotection and localized tissue repair, with tendon and gut models making up much of its record. TB-500 is a synthetic peptide based on the active region of thymosin beta-4, studied for actin sequestration, cell migration and angiogenesis, and described as acting systemically rather than only at one site. Angiogenesis is reported for both, so calling the two entirely separate oversimplifies them. Pairing them is an argument from two separate mechanism literatures. It is not a finding from a study that tested the two together.

Q: How strong is the human evidence for either compound?

Limited for both. A systematic review of BPC-157 in orthopedic sports medicine found the evidence base dominated by animal studies with minimal human data (Vasireddi et al., 2025). For TB-500, human clinical evidence in tissue healing is limited and no large randomized trials support the recovery claims commonly attached to it. The mechanisms are reproducible in the laboratory. The jump from those mechanisms to a proven human outcome has not been made for either compound.

Q: Are BPC-157 and TB-500 approved for human use?

No. Both are sold for research use rather than as approved therapies, and most research peptides are not FDA-approved for human or therapeutic use. BPC-157 has a specific regulatory history: the FDA placed it in Category 2 of the section 503A bulk drug substances program in 2023 and removed it from that Category 2 list in April 2026 pending a further Pharmacy Compounding Advisory Committee review. Status changes, so confirm the current position on the FDA page rather than relying on a snapshot.

The short answer

These two are discussed together because their primary published mechanisms are different, not because a study showed the combination beats either compound alone. BPC-157 research centers on cytoprotection and localized tissue repair. Thymosin beta-4, the protein behind TB-500, is studied for actin sequestration, cell migration and angiogenesis. No controlled study in the work cited below tested the two together, so the pairing is a mechanistic argument rather than a demonstrated result, and both evidence bases are dominated by animal and cell models. In practice a stack means two separate vials, reconstituted and stored separately.

General educational information, research-use framing only, not medical advice. This page describes what published research reports and does not set a protocol or a dose.

Why the pairing exists

Two compounds, two separate mechanism literatures

The case for running both rests on the observation that the two mechanism accounts are not the same account. They are not fully separate either, and the overlap is worth naming rather than smoothing over. BPC-157 is a synthetic pentadecapeptide whose research record is built on cytoprotection and repair in animal models, with angiogenic signaling described through the VEGF receptor 2 and nitric oxide pathway (Sikiric et al., 2020). Much of the musculoskeletal work is tendon-specific: BPC-157 promoted tendon-to-bone healing after Achilles detachment in rats (Krivic et al., 2006), and in tendon fibroblasts it was associated with tendon outgrowth, cell survival and cell migration (Chang et al., 2011) and with increased growth hormone receptor expression (Chang et al., 2014).

TB-500 is a different molecule with a different story. It is a synthetic peptide based on the active region of thymosin beta-4, one of the more abundant actin-binding proteins in the body. The core reported mechanism is actin sequestration: thymosin beta-4 binds actin monomers in a 1:1 complex that inhibits polymerization (Safer, Elzinga & Nachmias, 1991), which is what governs a cell changing shape and moving toward a wound edge (Goldstein, Hannappel & Kleinman, 2005). From there the literature describes cell migration and angiogenesis, including endothelial migration, adhesion and tubule formation mapped to a defined actin-binding site (Philp, Huff, Gho, Hannappel & Kleinman, 2003), and it is described as acting systemically rather than only at the injection site.

Compound	What research reports	Evidence base
BPC-157	Cytoprotection and tissue repair, with angiogenic signaling described through the VEGF receptor 2 and nitric oxide pathway	Review of animal-model work (Sikiric et al., 2020)
BPC-157	Tendon-to-bone healing after Achilles detachment, and tendon outgrowth, cell survival and cell migration in tendon fibroblasts	Rat Achilles models and tendon fibroblast studies (Krivic et al., 2006; Chang et al., 2011)
TB-500	Actin sequestration: thymosin beta-4 binds monomeric actin and regulates the cytoskeleton that lets a cell change shape and move	Biochemical and structural work, preclinical (Safer, Elzinga & Nachmias, 1991)
TB-500	Cell migration and angiogenesis, including endothelial migration, adhesion and tubule formation	Endothelial and wound-model assays, preclinical (Malinda et al., 1999; Philp et al., 2003)

The two accounts diverge at the primary mechanism and converge downstream. Cytoprotection is not actin sequestration, and those are the distinct starting points the pairing argument leans on. Angiogenesis is where they meet: it is described for BPC-157 through the VEGF receptor 2 and nitric oxide pathway (Sikiric et al., 2020) and for thymosin beta-4 through a mapped actin-binding site (Philp et al., 2003). So the honest version is complementary rather than non-overlapping, and a page that describes the two mechanisms as entirely separate has oversimplified them.

Read the table as four separate findings rather than one combined one. Every row comes from a study of a single compound, and the same sources already sit behind BPC-157 for tendon repair and TB-500 for healing on this site.

What is missing

Nothing in this reference set tested the two together

This is the part usually skipped. Every source cited on this page examines one compound in isolation. There is no controlled comparison of the pair against BPC-157 alone or TB-500 alone in this reference set, which means there is no combination effect size to quote, no reported interaction to describe, and no evidence-based answer to whether running both adds anything over running one. Complementary mechanisms are a reason to ask the question. They are not an answer to it.

The single-compound evidence is also thinner than the pairing language suggests. A systematic review of BPC-157 in orthopedic sports medicine found the evidence base dominated by animal studies with minimal human data (Vasireddi et al., 2025), and a 2025 narrative review of BPC-157 for musculoskeletal healing reached the same kind of conclusion about the state of the record (McGuire et al., 2025). For TB-500, human clinical evidence in tissue healing is limited and no large randomized trials support the recovery claims commonly attached to it; the published mechanistic and outcome work is dominated by cell cultures and animal models (Malinda et al., 1999; Bock-Marquette et al., 2004).

The honest summary

Two coherent laboratory stories about different mechanisms, each resting mainly on animal and cell work, and no study of the combination. Anyone describing the stack as a proven human protocol is reaching past what has been published.

Practical mechanics

What running two compounds actually involves

Setting the evidence question aside, a stack is a handling question, and it is the part people underestimate. Two compounds means two of everything: two vials, two reconstitutions, two concentrations to keep straight, and two sets of storage once the powder is in solution. None of the below is a protocol. It is what the logistics look like.

Separate vials, always

Both arrive as separate lyophilized powders. They are not supplied premixed and are not combined at home: once two compounds share a container there is no way to attribute anything that follows to one of them.

Separate reconstitution

Each vial is reconstituted on its own with bacteriostatic water. The concentration that results belongs to that vial only, so the arithmetic is done twice rather than once and carried across.

Different vial strengths

The two are not supplied at matching strengths. In our catalog BPC-157 is 20mg per vial and TB-500 is 10mg per vial, so identical volumes of water produce different concentrations and the per-vial math cannot be reused.

Separate storage and labeling

Lyophilized powder is stable at room temperature for weeks. Once reconstituted, vials are refrigerated, and two similar-looking vials in the same fridge are a labeling problem rather than a theoretical one.

The concentration arithmetic is the step that goes wrong most often, because it is done per vial and read in units rather than in mL. Our reconstitution calculator works it out for a given vial strength and water volume. Quantities themselves are not set here: there is no established human dose for either compound, and that decision belongs with a qualified clinician.

The single-vial alternative

KLOW is broader than this pair, not a packaged version of it

The blend that contains both compounds is KLOW, a four-peptide research blend in a single 80mg vial: BPC-157, TB-500, GHK-Cu and KPV. That is worth stating precisely, because it is often described as the BPC and TB stack in one vial and it is not. It contains those two plus a copper tripeptide studied for skin and collagen research and a short anti-inflammatory peptide, so it is a wider blend rather than the same pair packaged differently.

The real trade is fixed against independent. A blend is one vial, one reconstitution and one set of storage, at a ratio set at manufacture. Separate vials are more handling and more arithmetic, and each compound stays independent of the others. Neither arrangement changes the evidence position described above: there is no combination outcome data behind either one.

KLOW Combo →What each of the four peptides does →KPV, the fourth component →

Regulatory standing

Neither compound is approved for human use

Both are sold for research use rather than as approved therapies, and most research peptides are not FDA-approved for human or therapeutic use. BPC-157 carries a specific history worth knowing: the FDA placed it in Category 2 of the section 503A bulk drug substances program in 2023 and removed it from that Category 2 list in April 2026, pending a further Pharmacy Compounding Advisory Committee review. Because that picture moves, treat any statement here as a snapshot and confirm the current position on the FDA page listed in the references. The longer version of the legal question, including how status varies by jurisdiction, is on are peptides legal.

One caution that follows from the mechanism

Angiogenesis is part of the reported mechanism for both compounds, and new blood vessel formation is not always wanted. The caution published alongside these compounds on this site is that anyone with active cancer or a cancer history should discuss that mechanism with a physician first, and that there is no safety data supporting use in pregnancy or breastfeeding. That is a restatement of a published caution, not a safety assessment for any individual.

Keep reading

The two compounds separately, the blend, and the math

BPC-157 vs TB-500

The two compounds compared side by side, mechanism by mechanism.

BPC-157

The compound page, with the research reference and batch certificate.

TB-500

The compound page for the thymosin beta-4 fragment.

KLOW Combo

The four-peptide blend that contains both compounds, plus GHK-Cu and KPV.

Reconstitution calculator

Per-vial concentration math, worked in units rather than mL.

Best peptides for injury healing

Where each repair peptide sits by the evidence behind it.

BPC-157 and TB-500 stack: FAQ

References

Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167. doi:10.5009/gnl18490. PMID 31158953. PMCID PMC7096228.
Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989. doi:10.1002/jor.20096. PMID 16583442.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3). doi:10.1152/japplphysiol.00945.2010. PMID 21030672.
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066. PMID 25415472.
McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. doi:10.1007/s12178-025-09990-7. PMID 40789979. PMCID PMC12446177.
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. doi:10.1177/15563316251355551. PMID 40756949.
Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398.
Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x. PMID 10469335.
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. doi:10.1096/fj.03-0121fje. PMID 14500546.
Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000. PMID 15565145.
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004. PMID 16099219.
U.S. Food and Drug Administration. Section 503A bulk drug substances program: Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act, and the category 2 listing itself, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Every study cited above examines one of the two compounds on its own, and none tested BPC-157 and TB-500 in combination. Reference 12 is a regulatory listing rather than a study.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and how each batch is tested.

See BPC-157 See TB-500 Certificates of analysis

General educational information only, research-use framing, not medical advice. Both compounds are research materials rather than approved treatments, and no dose or protocol is provided or implied here. Consult a qualified professional before acting.